Tegoprubart is under clinical development by Eledon Pharmaceuticals and currently in Phase I for Kidney Transplant Rejection. According to GlobalData, Phase I drugs for Kidney Transplant Rejection have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tegoprubart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tegoprubart overview

Tegoprubart is under development for the treatment of amyotrophic lateral sclerosis (ALS), IgA nephropathy (IgAN), renal transplantation (kidney transplant rejection) and autoimmune nephritis including lupus nephritis. The drug candidate is a humanized anti-CD40L monoclonal antibody. It acts by targeting CD40 ligand (CD40L). It is administered through intravenous route.

It was also under development for the treatment of focal segmental glomerulosclerosis (FSGS), Type 1 diabetes, islet transplant rejection.

Eledon Pharmaceuticals overview

Eledon Pharmaceuticals is a biotechnology company. It develops products for the ear, nose, and throat. The company’s lead products are a nasally-administer, combination drug product, and eustachian tube dysfunction, among others. Its galeterone is an oral small molecule drug candidate for the treatment of patients with metastatic castration-resistant prostate cancer. Novus offers an OP-02 surfactant program and an OP-01 foam platform. Its pipeline also includes an androgen receptor degradation agent’s drug discovery program to identify and develop compounds for androgen receptor degradation activity. The company develops treatments for illnesses and disorders of the ears, nose, and throat. It has collaborated with pharmaceutical companies to enhance its product candidates. Eledon Pharmaceuticals is headquartered in Irvine, California, the US.

For a complete picture of Tegoprubart’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.